文献速递中医儿科中药与中成药合理使用

小儿至宝丸口服后砷形态蓄积与大鼠体内毒性研究

Accumulation of Arsenic Speciation and In Vivo Toxicity Following Oral Administration of a Chinese Patent Medicine Xiao-Er-Zhi-Bao-Wan in Rats.
PubMed 文献 · Front Pharmacol · 2017-07-25

该研究以大鼠为对象,观察含雄黄中成药小儿至宝丸口服后砷形态蓄积与毒性。结果显示肾DMA由18.57±7.45升至22.74±7.45 ng/g,为对照约10倍;总砷第7天185.52±24.56 ng/g、第14天198.57±26.26 ng/g近对照92.77±14.98 ng/g两倍;14天肝轻度损伤。

要点

  • 含雄黄中成药小儿至宝丸可致大鼠肾DMA蓄积,约为对照10倍
  • 总砷第7、14天近对照两倍,砷毒性呈浓度和时间依赖
  • 14天出现肝、肾轻度损伤,评价毒性宜测DMA而非总砷

核心结论

  • 小儿至宝丸砷毒性呈浓度和时间依赖,DMA蓄积与更高毒性相关。
  • 评价含雄黄中药毒性时测DMA可能比测总砷更合适。

研究设计与样本

  • 大鼠口服小儿至宝丸后,采用HPLC-ICP-MS测定砷形态并结合组织病理与血生化。

主要发现

  • 肾DMA由18.57±7.45升至22.74±7.45 ng/g,为对照约10倍。
  • 三价砷As(III)第7天26.99±1.98 ng/g,第14天降至13.67±6.48 ng/g。
  • 总砷第7天185.52±24.56 ng/g、第14天198.57±26.26 ng/g,近对照92.77±14.98 ng/g两倍。
  • 口服雄黄及小儿至宝丸14天均见肝、肾轻度损伤。

临床怎么用

  • 含雄黄中成药临床应关注用药时长与蓄积风险。
  • 毒性评估可优先检测DMA等砷形态而非仅测总砷。

局限性

  • 研究为大鼠实验,结论外推至人需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Realgar-containing traditional Chinese medicines such as Xiao-Er-Zhi-Bao-Wan (XEZBW), have been widely used for thousands of years. However, events associated with arsenic-induced ailments have increasingly become a public concern. To address the toxicity of XEZBW, we studied the histopathology and blood biochemistry of rats exposed to XEZBW using technology like high-performance liquid chromatography-inductively coupled mass spectrometry to determine arsenic speciation. Our results demonstrated that dimethylarsinic acid (DMA) increased from 18.57 ± 7.45 to 22.74 ± 7.45 ng/g in rat kidney after oral administration for 7 and 14 days, which was 10-fold higher than the levels observed in controls. Trivalent arsenite As(III) showed a large increase on day 7 (26.99 ± 1.98 ng/g), followed by a slight decrease on day 14 (13.67 ± 6.48 ng/g). Total arsenic levels on day 7 (185.52 ± 24.56 ng/g) and day 14 (198.57 ± 26.26 ng/g) were nearly twofold higher than that in the control group (92.77 ± 14.98 ng/g). Histopathological analysis showed mild injury in the liver and kidney of rats subjected to oral administration of realgar for 14 days. As in the XEZBW groups, a mild injury in these organs was observed after administration for 14 days. This study inferred that the toxicity of arsenic was concentration- and time-dependent. The accumulation of DMA, a byproduct of choline metabolism, was responsible for inducing higher toxicity. Therefore, we concluded that measuring the levels of DMA, instead of total arsenic, might be more suitable for evaluating the toxicity of realgar-containing traditional Chinese medicines.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Luo J, Han X, Dou X, et al. Accumulation of Arsenic Speciation and In Vivo Toxicity Following Oral Administration of a Chinese Patent Medicine Xiao-Er-Zhi-Bao-Wan in Rats. Front Pharmacol. 2017. PMID: 28790918. doi:10.3389/fphar.2017.00491

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。